Meeting highlights from the Pharmacovigilance Risk Assessment Committee
(PRAC) 1-3 October 2012
PRAC starts first referral procedure
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has started the first safety review of a medicine under the new EU rules on pharmacovigilance at its third meeting from 1 to 3 October 2012.
The safety review concerns codeine-containing medicines when used for post-operative pain relief in children. These medicines are only authorised nationally, at the level of the EU Member States. The PRAC will assess all available information and make a recommendation to the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). Under the new rules, the group leads on decision-making based on recommendations from the PRAC for nationally authorised medicines. These changes ensure harmonised implementation of safety recommendations across the EU.
New levels of transparency for safety reviews
The new pharmacovigilance legislation includes an explicit commitment to openness and transparency in the European medicines safety-monitoring system. For EU-wide safety reviews, the Agency now provides more information than ever before at the beginning of the safety review. Information made available to the public for the safety review of codeine-containing medicines includes:
- an information document on the review of codeine-containing medicines
- the notification of a referral made by the United Kingdom
- the list of questions drawn up by the PRAC to be addressed by the marketing authorisation holders
- the timetable for the procedure
For an overview of all information available following the meeting of the PRAC please see here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
